STOCK TITAN

Nuvectis Pharma Inc - NVCT STOCK NEWS

Welcome to our dedicated news page for Nuvectis Pharma (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvectis Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvectis Pharma's position in the market.

Rhea-AI Summary
Nuvectis Pharma, Inc. (NVCT) announces presentations for NXP800 and NXP900 at the 2024 AACR Meeting. NXP800 shows promise in treating ovarian cancer, while NXP900 demonstrates antitumor activity in cholangiocarcinoma models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.08%
Tags
conferences
-
Rhea-AI Summary
Nuvectis Pharma to present at the 36th Annual Roth Conference on March 19, 2024, focusing on precision medicines for oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.22%
Tags
conferences
-
Rhea-AI Summary
Nuvectis Pharma, Inc. (NVCT) announces positive preliminary data from Phase 1b clinical trial of NXP800 in platinum resistant ARID1a-mutated ovarian cancer patients. Results show a 33% response rate and 100% disease control rate. Fast Track Designation granted by FDA. Encouraging efficacy data observed in early patients, with manageable side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
clinical trial
Rhea-AI Summary
Nuvectis Pharma, Inc. provided an update on its two clinical-stage drug candidates, NXP800 and NXP900, with multiple clinical data readouts expected in 2024. The company reported a decrease in cash and cash equivalents, a net loss increase of $2.2 million, and higher research and development expenses in the fiscal year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
earnings
-
Rhea-AI Summary
Nuvectis Pharma, Inc. (NVCT) announced that Ron Bentsur will present at investor conferences, including Oppenheimer Healthcare Life Sciences Conference and NeauxCancer Oncology Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
-
Rhea-AI Summary
Nuvectis Pharma, Inc. (NVCT) announces Ron Bentsur, Chairman and CEO, will present at investor conferences. The company focuses on precision medicines for oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
Rhea-AI Summary
Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced that Ron Bentsur, Chairman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, to discuss the development of precision medicines for serious conditions in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences
-
Rhea-AI Summary
Nuvectis Pharma, a clinical-stage biopharmaceutical company (NASDAQ: NVCT), collaborates with Mayo Clinic to evaluate NXP800 in an Investigator-sponsored clinical trial for cholangiocarcinoma. Mitesh Borad, M.D., will serve as the Principal Investigator. NXP800 was granted orphan drug designation by the FDA for the treatment of cholangiocarcinoma in August 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
clinical trial
-
Rhea-AI Summary
NVCT: Nuvectis Pharma Reports Progress in Phase 1b Study of NXP800 in Ovarian Carcinoma and Financial Results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
earnings
Rhea-AI Summary
Nuvectis Pharma announces upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
Nuvectis Pharma Inc

Nasdaq:NVCT

NVCT Rankings

NVCT Stock Data

148.19M
5.11M
57.21%
16.94%
4.15%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Fort Lee